KR20000010667A - 병원성 에스케리히아 콜리 관련 단백질 - Google Patents

병원성 에스케리히아 콜리 관련 단백질 Download PDF

Info

Publication number
KR20000010667A
KR20000010667A KR1019980708638A KR19980708638A KR20000010667A KR 20000010667 A KR20000010667 A KR 20000010667A KR 1019980708638 A KR1019980708638 A KR 1019980708638A KR 19980708638 A KR19980708638 A KR 19980708638A KR 20000010667 A KR20000010667 A KR 20000010667A
Authority
KR
South Korea
Prior art keywords
espa
polypeptide
polynucleotide
coli
collie
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019980708638A
Other languages
English (en)
Korean (ko)
Inventor
비 브레트 핀레이
마르쿠스 스타인
브렌던 케니
Original Assignee
팜 윌리암 엔.
유니버시티 오브 브리티시 콜롬비아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 팜 윌리암 엔., 유니버시티 오브 브리티시 콜롬비아 filed Critical 팜 윌리암 엔.
Publication of KR20000010667A publication Critical patent/KR20000010667A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/245—Escherichia (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
KR1019980708638A 1996-04-23 1997-04-23 병원성 에스케리히아 콜리 관련 단백질 Withdrawn KR20000010667A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1599996P 1996-04-23 1996-04-23
US60/015,999 1996-04-23

Publications (1)

Publication Number Publication Date
KR20000010667A true KR20000010667A (ko) 2000-02-25

Family

ID=21774805

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019980708638A Withdrawn KR20000010667A (ko) 1996-04-23 1997-04-23 병원성 에스케리히아 콜리 관련 단백질

Country Status (10)

Country Link
US (4) US6355254B1 (https=)
EP (1) EP0904288B1 (https=)
JP (3) JP2000511771A (https=)
KR (1) KR20000010667A (https=)
AU (1) AU2562897A (https=)
BR (1) BR9710433A (https=)
CA (1) CA2252372C (https=)
DK (1) DK0904288T3 (https=)
ES (1) ES2389625T3 (https=)
WO (1) WO1997040063A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2252438C (en) * 1996-04-19 2011-03-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
BR9710433A (pt) 1996-04-23 1999-10-05 Univ British Columbia Proteínas associada a escherichia coli patogênica
US6204004B1 (en) * 1997-03-21 2001-03-20 University Of Maryland, Baltimore Immunodiagnostic test for enterohemorrhagic Escherichia coli infection
US7208574B1 (en) 1997-11-12 2007-04-24 The University Of British Columbia Host receptor for pathogenic bacteria
WO1999045136A1 (en) * 1998-03-05 1999-09-10 University Of British Columbia Methods for assaying type iii secretion inhibitors
US6342352B1 (en) 1998-04-24 2002-01-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of detecting shigella and shigella mxiM DNA
US6136542A (en) * 1998-05-13 2000-10-24 Institut Pasteur Method for screening for inhibitors and activators of type III secretion machinery in gram-negative bacteria
US6696249B1 (en) 1998-05-13 2004-02-24 Institut Pasteur Method for screening for inhibitors and activators of type III secretion machinery in gram-negative bacteria
WO2001073440A2 (de) * 2000-03-28 2001-10-04 Schebo Biotech Ag Nachweis von diarrhogenen e.coli-keimen
AU2002218927B2 (en) 2001-01-04 2007-08-30 The University Of British Columbia Enterohemorrhagic Escherichia coli vaccine
CA2339436A1 (fr) 2001-03-15 2002-09-15 Josee Harel Production d'anticorps contre les facteurs de virulence associes aux souches d'escherichia coli aeec, et leur utilisation
US20060241075A1 (en) * 2001-05-18 2006-10-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
WO2004050119A1 (en) * 2002-11-29 2004-06-17 Imperial College Innovations Limited Vaccine against enteropathogenic and enterohaemorragic escherichia coli
BRPI0415816A (pt) 2003-10-31 2006-12-26 Univ British Columbia composição, bactéria ou um preparado da mesma, método para detectar a presença de um patógeno de a/e em uma amostra, método para provocar uma resposta imunológica contra um patógeno de a/e ou um componente do mesmo em um animal, método para reduzir a colonização de um patógeno de a/e em um animal, método para reduzir a disseminação de um patógeno de a/e em um animal, método para o tratamento ou a prevenção da infecção por um patógeno de a/e, método para atenuar a virulência de um patógeno de a/e, método para a seleção de um composto que atenue a virulência de um patógeno e a/e, método para a produção de um polipeptìdio de patógeno de a/e, polipeptìdio recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, uso da composição e kit
GB0411624D0 (en) * 2004-05-25 2004-06-30 Imp College Innovations Ltd Products and uses thereof
JP5151477B2 (ja) 2005-04-28 2013-02-27 日立金属株式会社 半導体磁器組成物とその製造方法
WO2008133659A2 (en) 2006-11-29 2008-11-06 Tufts University Eschericia coli mutants and methods of use thereof
WO2009032978A2 (en) * 2007-09-07 2009-03-12 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating urinary tract infections
JP2012522522A (ja) 2009-04-06 2012-09-27 ユニバーシティー オヴ サスカチュワン 志賀毒素産生大腸菌感染を処置及び予防するための方法並びに組成物
US20110229512A1 (en) * 2010-03-19 2011-09-22 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating urinary tract infections
JP5714692B2 (ja) * 2010-03-23 2015-05-07 イーエムベーアー−インスティトゥート・フューア・モレクラレ・ビオテヒノロギー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＩｍｂａ−Ｉｎｓｔｉｔｕｔ Ｆｕｅｒｍｏｌｅｋｕｌａｒｅ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅ Ｇｍｂｈ Ｉｉｉ型分泌機構の阻害剤の同定方法
GB201621686D0 (en) * 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US15999A (en) 1856-10-28 Improved projectile for ordnance
CA2078716A1 (en) 1992-09-21 1994-03-22 Joyce De Azavedo Attaching and effacing protein of enterohemorrhagic e. coli
US6090623A (en) * 1993-08-11 2000-07-18 Merck & Co., Inc. Recombinant human calcium channel β4 subunits
BR9710433A (pt) * 1996-04-23 1999-10-05 Univ British Columbia Proteínas associada a escherichia coli patogênica

Also Published As

Publication number Publication date
US20060292180A1 (en) 2006-12-28
BR9710433A (pt) 1999-10-05
US20110003339A1 (en) 2011-01-06
CA2252372A1 (en) 1997-10-30
JP2010132698A (ja) 2010-06-17
CA2252372C (en) 2010-06-29
US20020115829A1 (en) 2002-08-22
ES2389625T3 (es) 2012-10-29
JP5058106B2 (ja) 2012-10-24
WO1997040063A3 (en) 1998-03-26
US7078193B2 (en) 2006-07-18
DK0904288T3 (da) 2012-09-24
AU2562897A (en) 1997-11-12
JP2000511771A (ja) 2000-09-12
US8021861B2 (en) 2011-09-20
EP0904288B1 (en) 2012-06-13
JP2009022294A (ja) 2009-02-05
US6355254B1 (en) 2002-03-12
EP0904288A2 (en) 1999-03-31
US7214499B2 (en) 2007-05-08
WO1997040063A2 (en) 1997-10-30

Similar Documents

Publication Publication Date Title
JP5058106B2 (ja) 病原性大腸菌関連タンパク質
Collazo et al. Functional analysis of the Salmonella typhimurium invasion genes invl and invJ and identification of a target of the protein secretion apparatus encoded in the inv locus
Vizcaíno et al. DNA polymorphism in the omp25/omp31 family of Brucella spp.: identification of a 1.7-kb inversion in Brucella cetaceae and of a 15.1-kb genomic island, absent from Brucella ovis, related to the synthesis of smooth lipopolysaccharide
Eko et al. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis
Domann et al. Identification and characterization of a novel PrfA-regulated gene in Listeria monocytogenes whose product, IrpA, is highly homologous to internalin proteins, which contain leucine-rich repeats
JP2026026153A (ja) 遺伝子改変ラクトバチルス（Ｌａｃｔｏｂａｃｉｌｌｕｓ）及びその使用
Altarriba et al. A polar flagella operon (flg) of Aeromonas hydrophila contains genes required for lateral flagella expression
JP2009173667A (ja) 病原菌のｔｉｒ遺伝子によってコードされる、病原菌の宿主の膜受容体、ｈｐ９０
Angelos et al. Identification and characterization of complete RTX operons in Moraxella bovoculi and Moraxella ovis
Balraj et al. Advances in Rickettsia pathogenicity
Mallavia et al. The genetics of Coxiella burnetii: etiologic agent of Q fever and chronic endocarditis
JP5770795B2 (ja) 細胞膨張化致死毒を標的としたカンピロバクター属細菌の検出
US20070003568A1 (en) Secreted chlamydia polypeptides, polynucleotides coding therefor, therapeutic and diagnostic uses thereof
WO1999045136A1 (en) Methods for assaying type iii secretion inhibitors
Ludwig et al. Haemolysins of Escherichia coli
WO1999045120A2 (en) Attenuation of bacteria: materials and methods relating thereto
Foley et al. Monoclonal antibodies to avian Escherichia coli Iss
MXPA98008795A (es) Proteina asociada con escherichia coli patogena
CN1222937A (zh) 致病性大肠杆菌相关蛋白
Plaut et al. Differential Gene Expression from Two
Henderson Development of new approaches to identify and characterise Campylobacter jejuni genes

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19981023

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid